NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
31/12/2024
Voltar para busca
Dado oficial do USPTO
CRINETICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
31/12/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
17/03/2023
Data de registro
31/12/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/12/2024
Última transação
31/12/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
07/12/2018
Primeiro uso no comércio
07/12/2018
Código do desenho
4
Tipo de titular
03
Localização do titular
San Diego, CA
Examinador
STOIDES, KATHERINE
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Crinetics Pharmaceuticals, Inc.
Representantes
Danny M. Awdeh FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of canceracromegalyneuroendocrine tumorsCushing's Diseasehyperinsulinismcarcinoid syndromecongenital adrenal hyperplasiahypercalcemiachronic painhyperparathyroidismpolycystic kidney diseaseGrave's diseasethyroid eye diseasethyroid ophthalmopathydiabetesobesityinsulinomahypoglycemiaandrogen deficiencyinfertilitythyroid cancergrowth hormone deficiencyhypoparathyroidismnonfunctional pituitary adenomaspolycystic liver diseasetype two diabetes; therapeutic preparations for the treatment of ocular diseases and disordersmetabolic diseases and disordershormonal diseases and disordersreproductive diseases and disordersbone diseases and disordersdigestive diseases and disordersgastroenterological diseases and disordersthyroid diseases and disorders
Classe 42
Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and developmentresearch and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancerendocrine disordersacromegalyneuroendocrine tumorsCushing's Diseasehyperinsulinismchronic painhypercalcemiahyperparathyroidismpolycystic kidney diseaseGrave's diseasethyroid eye diseasethyroid ophthalmopathydiabetesobesityinsulinomahypoglycemiaandrogen deficiencyinfertilitythyroid cancergrowth hormone deficiencyhypoparathyroidismnonfunctional pituitary adenomaspolycystic liver diseasetype two diabetes; pharmaceutical research for treating cancerendocrine disordersacromegalyneuroendocrine tumorsCushing's Diseasehyperinsulinismchronic painhypercalcemiahyperparathyroidismpolycystic kidney diseaseGrave's diseasethyroid eye diseasethyroid ophthalmopathydiabetesobesityinsulinomahypoglycemiaandrogen deficiencyinfertilitythyroid cancergrowth hormone deficiencyhypoparathyroidismnonfunctional pituitary adenomaspolycystic liver diseasetype two diabetes; therapeutic researchresearch of therapeutic preparations for ocular diseases and disordersmetabolic diseases and disordershormonal diseases and disordersreproductive diseases and disordersbone diseases and disordersdigestive diseases and disordersgastroenterological diseases and disordersthyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
31/12/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/12/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/12/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
14/11/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
13/11/2024
IUAF
USE AMENDMENT FILED
12/09/2024
EISU
TEAS STATEMENT OF USE RECEIVED
12/09/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/09/2024
EX1G
SOU EXTENSION 1 GRANTED
12/09/2024
EXT1
SOU EXTENSION 1 FILED
12/09/2024
EEXT
SOU TEAS EXTENSION RECEIVED
12/09/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
26/03/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
28/02/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
28/02/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
28/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/01/2024
PUBO
PUBLISHED FOR OPPOSITION
30/01/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/01/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/12/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
19/12/2023
ALIE
ASSIGNED TO LIE
19/12/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
18/12/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
18/12/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
18/12/2023
DOCK
ASSIGNED TO EXAMINER
13/12/2023
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
09/10/2023
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
09/10/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/04/2023
NWAP
NEW APPLICATION ENTERED
21/03/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CRINETICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.